Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Uptake of IgG after intramuscular and subcutaneous injection.

× No keyword cloud information.

18 in total

1. Septicaemic low birthweight neonates treated with human antibodies to endotoxin.

Authors: M Adhikari; H M Coovadia; S L Gaffin; J G Brock-Utne; M Marivate; D J Pudifin
Journal: Arch Dis Child Date: 1985-04 Impact factor: 3.791

2. Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers.

Authors: J Goodrick; B Kumpel; D Pamphilon; I Fraser; G Chapman; B Dawes; D Anstee
Journal: Clin Exp Immunol Date: 1994-10 Impact factor: 4.330

3. Turnover rate of anti-D IgG injected during pregnancy.

Authors: J Eklund; M Hermann; H Kjellman; P Pohja
Journal: Br Med J (Clin Res Ed) Date: 1982-03-20

4. Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis.

Authors: G R Siber; D M Ambrosino; J McIver; T J Ervin; G Schiffman; S Sallan; G F Grady
Journal: Infect Immun Date: 1984-07 Impact factor: 3.441

5. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors: R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal: Clin Exp Immunol Date: 2008-03-12 Impact factor: 4.330

6. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors: Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal: Ther Clin Risk Manag Date: 2010-02-02 Impact factor: 2.423

7. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.

Authors: Jennifer Heimall; Junliang Chen; Joseph A Church; Rhonda Griffin; Isaac Melamed; Gary I Kleiner
Journal: J Clin Immunol Date: 2016-06-25 Impact factor: 8.317

Review 8. [Therapeutic use of immunoglobulins in children (author's transl)].

Authors: W H Hitzig
Journal: Blut Date: 1980-03

9. Controlled trial of various anti-D dosages in suppression of Rh sensitization following pregnancy. Report to the Medical Research Council by the working party on the use of anti-D-immunoglobulin for the prevention of isoimmunization of Rh-negative women during pregnancy.

Authors:
Journal: Br Med J Date: 1974-04-13

10. Intravenous immunoglobulin therapy for antibody deficiency.

Authors: M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal: Clin Exp Immunol Date: 1979-05 Impact factor: 4.330